Prevalence of high‐risk HPV and its genotypes—Implications in the choice of prophylactic HPV vaccine

2021 ◽  
Author(s):  
Alka Suresh ◽  
Parasmal Suresh ◽  
Raja Biswas ◽  
Anupama Rajanbabu ◽  
Sarala Sreedhar ◽  
...  
Keyword(s):  
High Risk ◽  
Hpv Vaccine ◽  
High Risk Hpv ◽  
Prophylactic Hpv Vaccine

scholarly journals Prevalence, Incidence, and Clearance of Human Papillomavirus Types Covered by Current Vaccines in Men With Human Immunodeficiency Virus in the SUN Study

2019 ◽  
Vol 222 (2) ◽  
pp. 234-242 ◽  
Author(s):  
Pragna Patel ◽  
Tim Bush ◽  
Lois Conley ◽  
Elizabeth R Unger ◽  
Teresa M Darragh ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Papillomavirus ◽  
High Risk ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
Abnormal Cytology ◽  
Immunodeficiency Virus ◽  
Vaccine Impact ◽  
Sex With Men ◽  
High Risk Hpv

Abstract Background High-risk anal human papillomavirus (HPV) infection is prevalent among men living with human immunodeficiency virus (HIV); the association between 9-valent (9v) high-risk HPV (HR-HPV) vaccine types and abnormal cytology has not been well characterized. Methods We followed a prospective cohort study of persons with HIV at 7 HIV clinics in 4 US cities from March 2004 through June 2012. Annually, providers collected separate anal swabs for HPV detection and cytopathologic examination. Among men, we examined prevalence, incidence, and clearance of 9v HR-HPV vaccine types, compared with other HR types, and associations with abnormal cytology to assess potential vaccine impact. Results Baseline prevalence of any anal 9v HR-HPV type among men who have sex with men (MSM) and men who have sex with women (MSW) was 74% and 25% (P < .001), respectively. Among 299 MSM, abnormal cytology was detected in 161 (54%) MSM and was associated with the presence of any 9v HR-HPV (relative risk [RR], 1.8 [95% confidence interval {CI}, 1.3–2.6]; P < .001). Among 61 MSW, abnormal anal cytology was detected in 12 (20%) and was associated with the presence of any 9v HR-HPV (RR, 4.3 [95% CI, 1.6–11.5]; P < .001). Conclusions Among men with HIV, the prevalence of the 7 HR-HPV types in the 9v vaccine was high and was associated with abnormal cytology. These findings indicate that men with HIV could benefit from prophylactic administration of the 9v HPV vaccine.

scholarly journals Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections

2015 ◽  
Vol 213 (6) ◽  
pp. 939-947 ◽  
Author(s):  
Ariana Harari ◽  
Zigui Chen ◽  
Ana Cecilia Rodríguez ◽  
Allan Hildesheim ◽  
Carolina Porras ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Hpv Vaccine ◽  
Cross Protection ◽  
High Risk Hpv

scholarly journals HPV Vaccination: Prevention of Cervical Cancer in Serbia and in Europe

2018 ◽  
Vol 35 (1) ◽  
pp. 5-16
Author(s):  
Holger Stark ◽  
Aleksandra Živković
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
Low Risk ◽  
Vaccination Rates ◽  
Protection Efficacy ◽  
Efficient Protection ◽  
Hpv Types ◽  
High Risk Hpv

Summary The identification of the high-risk human papilloma viruses (HPVs) as a cause of cervical cancer offered the possibility for the development of a HPV vaccine. Twenty years after this identification of the HPV types, the first HPV vaccine came to the market. There are three HPV vaccines today on the market, all containing the virus-like particles (VLPs) of the HPV types 16 and 18, which are considered to cause 77 % of all cancers caused by HPVs. In addition, two of the vaccines contain two low-risk HPV types (6 and 11)-quadrivalent or the same as low-risk types and additional high-risk HPV types (31, 32, 45, 52, 58)-nonavalent vaccines. The cervical cancer protection efficacy of the vaccines is very high, around 100%. The VLPs of the 6- and 11-type offer efficient protection against genital warts. Unfortunately, the implementation of the vaccination is actually not so high despite all scientific and medical facts, but their rates in Europe are steadily increasing reaching about 90% in one country after another. In Serbia, all of the three vaccines are on the market but are highly underused. Actually, there is no national program and the Serbian vaccination rates are very low. High vaccination rates in Serbia need to be achieved as a goal of prevention of cervical cancer.

scholarly journals Surveillance of Human Papilloma Virus Using Reference Laboratory Data for the Purpose of Evaluating Vaccine Impact

2014 ◽  
Vol 6 (3) ◽  
Author(s):  
Andrew Wilson ◽  
Ryan J Welch ◽  
Mia Hashibe ◽  
Jessica Greenwood ◽  
Brian Jackson ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Hpv Vaccine ◽  
Quantitative Methods ◽  
Age Groups ◽  
The United States ◽  
Downward Trend ◽  
Reference Laboratory ◽  
High Risk Hpv ◽  
The Impact

Nationwide positivity rates of high-risk human papillomavirus for the United States before and since the introduction of a Human Papillomavirus (HPV) vaccine in 2006 would provide insight into the population impact of HPV vaccination.  Data for high-risk HPV testing results from January 1, 2004 to June 1, 2013 at a national reference laboratory were retrospectively analyzed to produce 757,761 patient records of women between the ages of 14 and 59. Generalized linear models and finite mixture models were utilized to eliminate sources of bias and establish a population undergoing standard gynecological screening. Unadjusted positivity rates for high-risk HPV were 27.2% for all age groups combined.  Highest rates occurred in women aged 14 to 19.  While the positivity rates decreased for all age groups from 2004 to 2013, the higher age categories showed less downward trend following vaccine introduction, and the two age categories 20 to 24 and 25 to 29 showed a significantly different downward trend between pre- and post-vaccine time periods (-0.1% per year to -1.5% per year, and 0.4 % per year to -1.5% per year, respectively).  All other age groups had rates of change that became less negative, indicating a slower rate of decline.In evaluating the surveillance tool, we find that it is important to consider many sources of heterogeneity, e.g., age, type of test, location, and type of testing center, and also consider quantitative methods of adjustment and distribution assessment to construct a useful surveillance tool.  Further studies should expand on this methodology.The results of the surveillance tool indicate a downward trend in vaccine-appropriate age groups consistent with uptake of the HPV vaccine. The pre-post rate changes were in direct contrast between the age-appropriate groups and the groups too old for the HPV vaccine, further indicating the surveillance tool may be detecting the impact of the HPV vaccine over time. After refinement, this surveillance tool should remain in place to observe the future impact of the HPV vaccine. 

Relative prevalence of high risk HPV genotypes in a US population: Insights before rollout of the next generation 9-valent HPV vaccine

2015 ◽  
Vol 137 ◽  
pp. 16 ◽  
Author(s):  
W.K. Huh ◽  
C.M. Behrens ◽  
J. Monsonego ◽  
T. Cox ◽  
M.T. Sandri ◽  
...  
Keyword(s):  
High Risk ◽  
Hpv Vaccine ◽  
Next Generation ◽  
Hpv Genotypes ◽  
Relative Prevalence ◽  
High Risk Hpv

scholarly journals Genotype of Human Papilloma virus in Male Genital Warts In Korean Men and Review of Literature

2021 ◽  
Author(s):  
Jung Joo Moon ◽  
Woo Chul Moon ◽  
Jinhan Yoon ◽  
Jungho Jo
Keyword(s):  
High Risk ◽  
Hpv Vaccine ◽  
Genital Warts ◽  
Hpv Infection ◽  
Single Infection ◽  
Anogenital Warts ◽  
Hpv Dna ◽  
Hpv Types ◽  
High Risk Hpv ◽  
Male Genital

Purpose: Genital warts are one of the most common sexually transmitted infections and related to human papillomavirus (HPV) infection. However, their prevalence and subtypes in male genital warts remains poorly defined. HPV vaccine is administered to men in part to prevent anogenital warts and it is important to investigate their expected impact in male anogenital warts. Materials and Methods: We have herein conducted a multicenter, prospective study to analyze HPV type distribution in genital warts of 1000 Korean men by using DNA microarray that can detect 40 types of genital HPV. Results: 1000 out of 1015 genital warts showed HPV DNA. Out of 1000 HPV-positive samples, 18.8% showed mixed infection and 81.2% showed single infection. Of 18 high-risk (16.2%) and 14 low-risk (94.3%) HPV types detected, the most common type of HPV types were HPV6 (59.5%), followed by HPV11 (24.3%), HPV16 (5.8%), HPV91 (5.3%), HPV40 (3.3%). 85.9% showed the 9 HPV types covered by the vaccine. Sixteen of the 200 HPV specimens submitted for sequencing showed discrepant results compared to the DNA sequencing. Conclusions: Male genital warts predominantly show HPV 6 and 11. However, high-risk HPV is not uncommon and the role of high-risk HPV in genital warts may be considered. The Gardasil 9 HPV vaccine is expected to provide protection against about >80% of male genital warts. Further HPV typing studies in male genital warts are necessary in other races and geographical areas to define the role and management of high-risk type HPV in male genital warts.

scholarly journals HPV Vaccine Protein L1 Predicts Disease Outcome of High-Risk HPV+ Early Squamous Dysplastic Lesions

2009 ◽  
Vol 132 (6) ◽  
pp. 840-845 ◽  
Author(s):  
Henrik Griesser ◽  
Heinz Sander ◽  
Cindy Walczak ◽  
Ralf A. Hilfrich
Keyword(s):  
High Risk ◽  
Hpv Vaccine ◽  
Disease Outcome ◽  
High Risk Hpv

scholarly journals High prevalence of high-risk HPV genotypes other than 16 and 18 in cervical cancers of Curaçao: implications for choice of prophylactic HPV vaccine

2017 ◽  
Vol 94 (4) ◽  
pp. 263-267 ◽  
Author(s):  
Desiree J Hooi ◽  
Birgit I Lissenberg-Witte ◽  
Maurits N C de Koning ◽  
Herbert M Pinedo ◽  
Gemma G Kenter ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
High Risk ◽  
Hpv Vaccine ◽  
Precancerous Lesions ◽  
Cervical Cancers ◽  
Hpv Genotypes ◽  
Hpv Types ◽  
Dna Enzyme Immunoassay ◽  
High Risk Hpv

BackgroundCuraçao is a Dutch-Caribbean Island located in a high-risk area for cervical cancer.Prior to introduction of a prophylactic human papillomavirus (HPV) vaccine, knowledge of the prevalence of high-risk HPV vaccine genotypes (HPV16, 18, 31, 33, 45, 52 and 58) in cervical (pre)cancer is required.ObjectiveTo investigate the prevalence of HPV genotypes in invasive cervical cancers (ICC) and cervical intraepithelial neoplasia (CIN) grade 1, 2 and 3 in Curaçao.MethodsParaffin-embedded blocks of 104 cervical cancers (89 squamous, 15 adenocarcinoma), 41 CIN3, 39 CIN2 and 40 CIN1 lesions were analysed for the presence of HPV. Sections were stained by H&E for histopathological evaluation, and DNA was extracted using proteinase K. HPV genotypes were detected using Short PCR Fragment (SPF10) PCR DNA enzyme immunoassay and a Line Probe Assay (LiPA25) .ResultsHPV was found in 92 (88.5%) ICC; 87 (94.6%) had a single HPV infection and 86 (93.5%) were high-risk human papillomavirus (hrHPV)-type positive.The three most common HPV types in ICC were 16 (38.5%), 18 (13.5%) and 45 (6.7%), covering 58.7%.HrHPV vaccine genotypes 16, 18, 31, 35, 45, 52 and 58 were responsible for 73.1% of ICC. For precancerous lesions, the HPV attribution was 85.4% for CIN3, 66.7% for CIN2% and 42.5% for CIN1.ConclusionsOur study, the largest in the Caribbean region in (pre)cancer, shows that the prevalence of HPV-type 16 and 18 in cervical cancer is lower compared with the world population but no differences in prevalence of these two HPV types are seen in precancerous lesions.When considering HPV vaccination in Curaçao, the relatively high contribution of non-HPV 16/18 genotypes in ICC should be taken into account.

Sign in / Sign up

Export Citation Format

Share Document